EXT2
Overview
EXT2 (exostosin glycosyltransferase 2) encodes a glycosyltransferase required for heparan sulfate biosynthesis and is a known tumor suppressor associated with hereditary multiple exostoses. In cancer pharmacogenomics, EXT2 variants were identified among the genomic features significantly correlated with erlotinib sensitivity in the CCLE pan-cancer profiling study.
Alterations observed in the corpus
- EXT2 variants are significantly correlated with erlotinib sensitivity across 947 cancer cell lines in the CCLE pharmacogenomic profiling study PMID:22460905
Cancer types (linked)
- EXT2’s association with erlotinib sensitivity was identified pan-cancer across 947 cell lines of diverse lineages in the CCLE; specific lineage enrichment was not detailed in the corpus PMID:22460905
Co-occurrence and mutual exclusivity
- EXT2 variants co-occur with EGFR mutations as features of erlotinib-sensitive lines in the CCLE, though the mechanistic relationship is not established PMID:22460905
Therapeutic relevance
- EXT2 variants predict erlotinib sensitivity in the CCLE pharmacogenomic dataset; the biological mechanism linking EXT2 loss-of-function and EGFR inhibitor sensitivity is not characterised in the corpus PMID:22460905
Open questions
- The mechanism by which EXT2 variants confer erlotinib sensitivity — potentially via effects on heparan sulfate proteoglycan-mediated receptor signalling — requires experimental validation.
Sources
This page was processed by entity-page-writer on 2026-05-06.